Zaire Ebola virus (EBOV) is a fatal human pathogen, with a high case fatality rate (CFR) averaging up to 78%. In March 2014, the World Health Organization (WHO) was made aware of a ZEBOV outbreak in rural Guinea, West Africa. Epidemiologic investigation linked the clinical and laboratory confirmed cases with the presumed first fatality of the outbreak in December 2013. EBOV from Guinea is a separate clade from other ZEBOV strains reported from the Democratic Republic of Congo (DRC) and Gabon. Since the outbreak in March, ZEBOV was also reported in Conakry, Guinea's capital and spread to other neighboring countries. In its largest outbreak, ZEBOV disease expanded through Guinea, Liberia, Sierra Leone, and Nigeria and to Spain, the USA, and the UK. The WHO declared the 2013-2015 West African Ebola epidemic a public health emergency of international concern considering its presumable capacity for further international spread. Early manifestations of EVD (Ebola virus disease) include a high fever, body aches, malaise, and fatigue. Severe diarrhea and other gastrointestinal manifestations such as vomiting were common, while bleeding was a more sporadic finding. The fatality rate was 43% and highest in patients aged ≥ 45 years and the overall fitted mean incubation period was 10.3 days (95% CI 9.9~10.7). We present a review of the literature on the emergence of Ebola, and the epidemiologic, clinical, and laboratory records of patients in whom EVD was diagnosed in Sierra Leone, Guinea, Liberia, Mali, the USA, and Spain, its zoonotic origin, and the transmission of ZEBOV, as well as presenting original literature on the current Ebola outbreak.
I. INTRODUCTION

A case fatality rate (CFR) of Ebola virus disease (EVD)
is 30 to 90%, depending on the virus species (1) Africa. However, this subregion was not considered to be an EBOV endemic region (2) . This outbreak then quickly spread to encircling areas, making it the largest EVD epidemic thus far ( EVD is identified as the causative agent of Ebola hemorrhagic fever, a severe form of viral hemorrhagic fever in 
II. The Emergence of EVD in Guinea 2013
In March 2014, the WHO received report of an outbreak of an infectious disease in Guinea characterized by fever, emesis, severe diarrhea, and a high fatality rate. Clinical microbiologic studies identified EBOV as the causative agent.
Full-length genome sequencing of viral pathogen and phylogenetic analysis showed that the EBOV from Guinea is in fact a separate clade from other known EBOV strains from the Gabon and DRC. Through epidemiologic investigation, the confirmed cases were connected to a 2-year-old boy 
V. Clinical manifestations in patients with Ebola
Index cases of Guinea predominantly showed clinical features such as fever, severe diarrhea, and emesis in Of the 106 patients diagnosed with EVD, 87 had a known outcome, and 44 were available detailed clinical information.
The incubation period was 6 to 12 days, the CFR was 74%, and the incubation period and CFR among EVD patients in Sierra Leone are similar to those observed elsewhere in the 2014 outbreak and in previous outbreaks.
Clinical features of EVD patients included fever (89%), headache (80%), dizziness (60%), weakness (66%), abdominal pain (40%), diarrhea (51%), and emesis (34% 
VI. The Transmission of Ebola Virus
Existing evidence suggests that direct contact with a patient and contaminated body fluids are the primary ways EBOV is transmitted. However, this is supported by few studies (3). EBOV is in the respirable range (800 to 1,000 nm) (21) .
